DK4019039T3 - Sammensætninger i form af en injicerbar vandig opløsning, som omfatter mindst et humant insulin A21G og en glucagonundertrykker med prandial virkning - Google Patents

Sammensætninger i form af en injicerbar vandig opløsning, som omfatter mindst et humant insulin A21G og en glucagonundertrykker med prandial virkning Download PDF

Info

Publication number
DK4019039T3
DK4019039T3 DK22156880.1T DK22156880T DK4019039T3 DK 4019039 T3 DK4019039 T3 DK 4019039T3 DK 22156880 T DK22156880 T DK 22156880T DK 4019039 T3 DK4019039 T3 DK 4019039T3
Authority
DK
Denmark
Prior art keywords
compositions
aqueous solution
human insulin
injectable aqueous
prandial action
Prior art date
Application number
DK22156880.1T
Other languages
English (en)
Inventor
You-Ping Chan
Original Assignee
Adocia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR1757172A external-priority patent/FR3069436A1/fr
Priority claimed from FR1757184A external-priority patent/FR3069437A1/fr
Priority claimed from FR1855250A external-priority patent/FR3082426A1/fr
Application filed by Adocia filed Critical Adocia
Application granted granted Critical
Publication of DK4019039T3 publication Critical patent/DK4019039T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK22156880.1T 2017-07-27 2018-07-27 Sammensætninger i form af en injicerbar vandig opløsning, som omfatter mindst et humant insulin A21G og en glucagonundertrykker med prandial virkning DK4019039T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR1757172A FR3069436A1 (fr) 2017-07-27 2017-07-27 Compositions sous forme d'une solution aqueuse injectable comprenant au moins de l'insuline humaine a21g et un suppresseur de glucagon a action prandiale
FR1757184A FR3069437A1 (fr) 2017-07-28 2017-07-28 Compositions sous forme d'une solution aqueuse injectable comprenant au moins de l'insuline humaine a21g et un suppresseur de glucagon a action prandiale
FR1855250A FR3082426A1 (fr) 2018-06-14 2018-06-14 Compositions sous forme d'une solution aqueuse injectable comprenant au moins de l'insuline humaine a21g et un suppresseur de glucagon a action prandiale
EP18746942.4A EP3658115B1 (fr) 2017-07-27 2018-07-27 Compositions sous forme d'une solution aqueuse injectable comprenant au moins l'insuline humaine a21g et un suppresseur de glucagon a action prandiale

Publications (1)

Publication Number Publication Date
DK4019039T3 true DK4019039T3 (da) 2024-01-15

Family

ID=63047385

Family Applications (1)

Application Number Title Priority Date Filing Date
DK22156880.1T DK4019039T3 (da) 2017-07-27 2018-07-27 Sammensætninger i form af en injicerbar vandig opløsning, som omfatter mindst et humant insulin A21G og en glucagonundertrykker med prandial virkning

Country Status (16)

Country Link
US (2) US10610572B2 (da)
EP (2) EP3658115B1 (da)
JP (2) JP7240004B2 (da)
KR (1) KR102757948B1 (da)
CN (1) CN110996905B (da)
AU (3) AU2018308692A1 (da)
BR (1) BR112020001617A2 (da)
CA (1) CA3071064A1 (da)
DK (1) DK4019039T3 (da)
ES (2) ES2969277T3 (da)
IL (1) IL272141B2 (da)
MA (1) MA49678A (da)
PH (1) PH12020500122A1 (da)
PL (2) PL3658115T3 (da)
SG (1) SG11202000625PA (da)
WO (1) WO2019020820A2 (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201607918D0 (en) 2016-05-06 2016-06-22 Arecor Ltd Novel formulations
DK4019039T3 (da) * 2017-07-27 2024-01-15 Adocia Sammensætninger i form af en injicerbar vandig opløsning, som omfatter mindst et humant insulin A21G og en glucagonundertrykker med prandial virkning
FR3082426A1 (fr) * 2018-06-14 2019-12-20 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant au moins de l'insuline humaine a21g et un suppresseur de glucagon a action prandiale
EP3915571A1 (en) 2020-05-29 2021-12-01 Adocia Pharmaceutical composition in the form of an injectable aqueous solution including at least a rapid acting insulin analog and a glucagon suppressor with prandial action
EP3915572A1 (en) 2020-05-29 2021-12-01 Adocia Pharmaceutical composition in the form of an injectable aqueous solution including at least a rapid acting insulin analog and a glucagon suppressor with prandial action
EP4144362A1 (en) * 2021-09-06 2023-03-08 Adocia Compositions comprising short-acting hormones for treating or preventing obesity and pumps comprising said composition
EP4129324A1 (en) * 2021-08-02 2023-02-08 Adocia Compositions comprising at least an amylin receptor agonist and a glp-1 receptor agonist
EP4342486A1 (en) 2022-09-20 2024-03-27 Adocia Compositions comprising at least an insulin and an amylin receptor agonist for treating diabetes, in a patient/person having a bmi of more than 28 kg/m² and/or an hba1c of more than 7.6 %

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5008241A (en) 1985-03-12 1991-04-16 Novo Nordisk A/S Novel insulin peptides
CA1295330C (en) 1985-03-29 1992-02-04 James M. Greene Synthesis of inotropic imidazo(4,5-c) pyridine
GB8720115D0 (en) 1987-08-26 1987-09-30 Cooper G J S Treatment of diabetes mellitus
US5234906A (en) 1991-01-10 1993-08-10 Amylin Pharmaceuticals, Inc. Hyperglycemic compositions
HU222249B1 (hu) 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
AU7685894A (en) 1993-09-07 1995-03-27 Amylin Pharmaceuticals, Inc. Methods for regulating gastrointestinal motility
US6410511B2 (en) 1997-01-08 2002-06-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US7312196B2 (en) 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US6506724B1 (en) 1999-06-01 2003-01-14 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
US20080248999A1 (en) 2007-04-04 2008-10-09 Biodel Inc. Amylin formulations
JP5312054B2 (ja) * 2006-03-15 2013-10-09 ノボ・ノルデイスク・エー／エス アミリンとインスリンの混合物
WO2007135118A1 (en) 2006-05-24 2007-11-29 Novo Nordisk A/S Soluble, stable insulin-containing formulations
US9173991B2 (en) 2007-07-02 2015-11-03 Roche Diabetes Care, Inc. Device for drug delivery
US20100222251A1 (en) * 2007-09-11 2010-09-02 Novo Nordisk A/S Mixture comprising an amylin peptide and a protracted insulin
EP2060268A1 (en) 2007-11-15 2009-05-20 Novo Nordisk A/S Pharmaceutical compositions for pulmonary or nasal delivery of peptides
AU2011202239C1 (en) * 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
CN102199206B (zh) * 2011-03-17 2013-03-20 甘李药业股份有限公司 快速起效且在酸性条件下稳定的胰岛素类似物及其制剂
WO2013067022A1 (en) 2011-10-31 2013-05-10 Xeris Pharmaceuticals, Inc. Formulations for the treatment of diabetes
US20150174209A1 (en) 2012-05-25 2015-06-25 Amylin Pharmaceuticals. Llc Insulin-pramlintide compositions and methods for making and using them
US20160271226A1 (en) * 2013-09-30 2016-09-22 Wockhardt Limited Pharmaceutical composition
PE20171622A1 (es) * 2014-12-12 2017-11-02 Sanofi Aventis Deutschland Formulacion de relacion fija de insulina glargina/lixisenatida
DK4019039T3 (da) * 2017-07-27 2024-01-15 Adocia Sammensætninger i form af en injicerbar vandig opløsning, som omfatter mindst et humant insulin A21G og en glucagonundertrykker med prandial virkning

Also Published As

Publication number Publication date
CN110996905B (zh) 2026-03-17
EP4019039B1 (fr) 2023-10-11
ES2917893T3 (es) 2022-07-12
PH12020500122A1 (en) 2020-09-14
AU2025203948A1 (en) 2025-06-19
IL272141A (en) 2020-03-31
JP7240004B2 (ja) 2023-03-15
EP3658115A2 (fr) 2020-06-03
SG11202000625PA (en) 2020-02-27
CA3071064A1 (en) 2019-01-31
KR20200034779A (ko) 2020-03-31
WO2019020820A2 (fr) 2019-01-31
JP2020528439A (ja) 2020-09-24
PL4019039T3 (pl) 2024-03-18
CN110996905A (zh) 2020-04-10
ES2969277T3 (es) 2024-05-17
US20190054149A1 (en) 2019-02-21
EP4019039A1 (fr) 2022-06-29
WO2019020820A3 (fr) 2019-03-28
US10610572B2 (en) 2020-04-07
US11065305B2 (en) 2021-07-20
EP3658115B1 (fr) 2022-02-23
IL272141B2 (en) 2024-07-01
US20200188487A1 (en) 2020-06-18
AU2023202831A1 (en) 2023-05-25
PL3658115T4 (pl) 2022-08-08
BR112020001617A2 (pt) 2020-07-21
IL272141B1 (en) 2024-03-01
AU2018308692A1 (en) 2020-03-05
KR102757948B1 (ko) 2025-01-23
JP2023078143A (ja) 2023-06-06
MA49678A (fr) 2021-04-14
PL3658115T3 (pl) 2022-08-08

Similar Documents

Publication Publication Date Title
DK4019039T3 (da) Sammensætninger i form af en injicerbar vandig opløsning, som omfatter mindst et humant insulin A21G og en glucagonundertrykker med prandial virkning
IL291291A (en) A glucagon derivative and a preparation containing its long-term active conjugate
PL3727426T3 (pl) Analogi inkretyny i ich zastosowania
EP3615661C0 (en) BI- OR MULTI-DIFFERENTIATED ORGANOID
EP3398961A4 (en) TRIPLE ACTIVATOR TO ACTIVATE GLUCAGON, GLP-1 AND GIP RECEPTOR
EP3599885C0 (en) MEAT ANALOGUE COMPRISING AN AQUEOUS GELLING COMPOSITION
EP3341404C0 (en) NEW INSULIN ANALOGS AND THEIR USE
EP3626290C0 (en) SAFE INSULIN PEN NEEDLE
EP3856292C0 (en) SAFETY SYRINGE
IL275184A (en) Preparations in the form of an aqueous solution for injection that include human glucagon and copolyamino acid
DK3229828T3 (da) Formulering med fast forhold mellem insulin glargin og lixisenatid
DK3554534T3 (da) Farmaceutisk sammensætning omfattende insulin
DK3347006T3 (da) Deutererede analoger af etifoxin, derivater deraf og anvendelser deraf
IL261777A (en) Palatable compositions including sodium phenylbutyrate and uses thereof
IL266279A (en) Aqueous formulations, stability of pexacin for injection and medical uses thereof
DK3275454T3 (da) Farmaceutisk sammensætning med silybin, ve og l-carnitin
SG11202005320VA (en) Compositions in the form of an injectable aqueous solution comprising human glucagon and a copolyamino acid
EP3541397A4 (en) FAST-ACTING INSULIN ANALOGUE WITH IMPROVED STABILITY
IL253600A0 (en) Insulin analogs and preparations containing them
PT4073097T (pt) Novos análogos de insulina e suas utilizações
FR3042777B1 (fr) Aeronef a voilure fixe et a stabilite statique accrue
DK3634384T3 (da) Levodopa-infusionsopløsning
DK3773682T3 (da) Injicerbare doseringsformer, sprøjter og sammensætninger med forlænget og/eller kontrolleret frigivelse af lanreotid
EP3638348A4 (en) SAFETY SYRINGE
DK3288920T3 (da) Fremgangsmåde til fremstilling af methionin ?-hydroxy analoger af sukre og derivater deraf